Press Room

1. Lipohypertrophy, what's the big deal?

by: JDRF Canada
February 25, 2015
Lipohypertrophy, BD, JDRF

Well, besides having lumpy, “not-so-pretty” areas on your body, the main concern is that if you inject into a lipo, your insulin may not be absorbed the way it should be resulting in ups and downs in blood sugar control and the need for more insulin.

2. Lipohypertrophy, what the heck is it anyway?

by: JDRF Canada
February 23, 2015
Lipohypertrophy, type 1 diabetes, BD

Do you have diabetes? Do you take insulin? Do you have lipohypertrophy?

3. Lipo-What?

by: JDRF Canada
February 16, 2015
Lipohypertrophy, type 1 diabetes, T1D

Lipohypertrophy - a very long word for a very common occurrence for those living with type 1 diabetes (T1D). Interested in learning more? Stay tuned and join JDRF Canada and BD for Lipohypertrophy Awareness Week from February 23-27 to learn more and even meet Lipo Larry! ...

4. JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes

by: JDRF US
June 24, 2013
JDRF, BD, Becton

JDRF and BD (Becton, Dickinson and Company) (NYSE:BDX) are accelerating the development of new products that combine BD’s proprietary insulin infusion and glucose sensing technologies through a new collaboration announced today.

5. JDRF Launches Research Program to Accelerate Delivery of Faster Acting Insulin; Key Step on Road to an Artificial Pancreas

August 16, 2010
research, APP, BD

NEW YORK, August 16, 2010 - JDRF announced today another important step on the road to the development of an artificial pancreas - an automated system to better manage the blood sugar of people with type 1 diabetes - with the establishment of a research program to speed the development of faster-acting ...

6. JDRF and BD Collaborate to Improve Insulin Pump Delivery

January 19, 2010
BD, collaboration, control

New York, NY and Franklin Lakes, NJ (January 19, 2010) - The Juvenile Diabetes Research Foundation (JDRF) and BD (Becton, Dickinson and Company) (NYSE:BDX) announced today an innovative program aimed at improving the treatment of type 1 diabetes by developing novel insulin delivery products to enhance ...